The focus of the program is to select compounds using its proprietary Alzheimer’s disease (AD) screening assays active against tau oligomers, and to evaluate these compounds in a tauopathy mouse model.
James Moe, president and CEO of Oligomerix, said: “Tau oligomers play an important role in neurodegeneration and memory loss and are an emerging target for drug discovery for AD. We believe this study will enable the discovery of novel disease-modifying drugs for AD and other tauopathies.”